[Axitinib in metastatic renal carcinomas: update of knowledge about side effects].
OBJECTIVE
The objective of this article is to summarize the knowledge as for the side effects related to axitinib in terms of incidence, etiology and symptoms for the effects requiring a specific management.


METHODS
This article follows upon the recommendations for the clinical practice, published in 2011, which detailed the management of secondary specific toxicities related to targeted therapies prescribed for the treatment of metastatic renal cell carcinoma with a focus on axitinib.


RESULTS
Overall, the toxicity profile of axitinib is better the other tyrosine kinase inhibitors. The ENT side effects and polycythemia, which had not been initially described with other molecules, seem more frequent. Regarding management and follow-up of side effects with axitinib, as for the other targeted therapies used in metastatic renal carcinoma, there are no crucial changes since the recommendations of 2011.


CONCLUSIONS
The management of side effects remains similar to the recommendations published in 2011. Only preventive measures and management of ENT side effects and polycythemia must be integrated in new thesaurus.
Institut Gustave-Roussy, Département d'oncologie médicale, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.
Laurence
L
Albiges
CHU Pitié-Salpêtrière, Service de néphrologie, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
Hassan
H
Izzedine
CHU Saint-Antoine, Service de cardiologie, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
Stéphane
S
Ederhy
Institut Gustave-Roussy, Service de dermatologie, 94805 Villejuif, France.
Caroline
C
Robert
Institut Paoli-Calmettes, Département d'oncologie médicale, 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 9, France.
Gwenaëlle
G
Gravis
Centre Léon-Bérard, Département d'oncologie médicale, 28, rue Laennec, 69373 Lyon, France.
Helen
H
Boyle
Hôpital européen Georges-Pompidou, Service d'oncologie médicale, 20, rue Leblanc, 75908 Paris cedex 15, France.
Florian
F
Scotté
Institut Gustave-Roussy, Département d'oto-rhino-laryngologie, 94805 Villejuif, France.
Dana
D
Hartl
Institut Gustave-Roussy, Département d'oncologie médicale, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.
Bernard
B
Escudier
D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007191:Indazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib
axitinib; metastatic renal cell carcinoma; recommendations; side effects; tyrosine kinase inhibitors